CONTROLLED RELEASE NITAZOXANIDE IN COMBINATION WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN RESULTS IN HIGH EARLY VIROLOGIC RESPONSE RATES FOR TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4

Trial Profile

CONTROLLED RELEASE NITAZOXANIDE IN COMBINATION WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN RESULTS IN HIGH EARLY VIROLOGIC RESPONSE RATES FOR TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2011

At a glance

  • Drugs Nitazoxanide; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Romark Laboratories
  • Most Recent Events

    • 03 Apr 2011 Status changed from active, no longer recruiting to completed.
    • 26 Nov 2009 New trial record
    • 29 Oct 2009 Interim results presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top